Trinity Biotech will pay the amount with just over 270,000 Trinity Biotech plc’s American Depositary Shares and the rest in cash and assumption of liabilities.

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity ...

Trinity Biotech plc TRIB has completed its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM). This trial assessed the effectiveness of significant ...

Trinity Biotech’s Chief Technology Officer, Dr Gary Keating, added, “Our next phase of refinements, guided by this study’s positive results, will be tested in a second European pre-pivotal ...

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management, announced it has secured an additional $4 million in debt financing from Perceptive Advisors.

DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

The Jamestown facility of Trinity Biotech USA was recently recertified into the Safety & Health Achievement Recognition Program, also known as SHARP, for maintaining a highly-effective safety and ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ETCompany Participants. Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des ...

BOSTON (CBS.MW) -- Biotechnology stocks were edging higher in early trading Monday with shares of Trinity Biotech soaring after the Irish company said it won U.S. clearance for its 10-minute HIV ...

Trinity Biotech will pay the amount with just over 270,000 Trinity Biotech plc’s American Depositary Shares and the rest in cash and assumption of liabilities.